Physician

Christopher Brent Benton, M.D.

According to 2025 Medicare claims, Christopher Benton, M.D. (NPI: 1255667655) practices medical oncology in the Denver-Aurora-Centennial, CO market, with the plurality of this provider's patient population coming from Arapahoe, CO. This provider's primary affiliated billing organization is ROCKY MOUNTAIN CANCER CENTERS LLP (NPI: 1518941186; TIN: 841457488) and primary practice location at 80112-4046.

Benton's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 665 traditional Medicare patients, billed 174,457 HCPCS/CPT codes, and received $2,932,037 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,866 prescription claims across 246 beneficiaries totaling $11,792,032 in drug costs, led by Jakafi (Ruxolitinib Phosphate). Open Payments data shows 125 records totaling $138,297. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $12,993 to $2,932,037. Similarly, Part D prescription costs have moved sharply higher in recent years, from $3,184 to $11,792,032. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	29	146	$12,993
2016	127	691	$59,923
2017	103	801	$70,302
2018	83	594	$52,938
2019	277	12,926	$268,105
2020	458	62,732	$952,942
2021	627	189,506	$2,750,899
2022	665	200,515	$2,202,222
2023	669	223,933	$3,097,727
2024	665	174,457	$2,932,037

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	17	35	$3,184
2016	48	275	$119,855
2017	47	276	$352,604
2018	39	223	$532,655
2019	102	460	$1,300,759
2020	135	1,030	$2,428,991
2021	172	1,391	$5,333,335
2022	199	1,210	$5,643,638
2023	231	1,587	$9,506,242
2024	246	1,866	$11,792,032

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	247	550	$95
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	246	611	$13
80053	Blood test, comprehensive group of blood chemicals	249	1,346	$10
36415	Insertion of needle into vein for collection of blood sample	292	1,704	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	289	1,828	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	343	10,290	$5,721,044
Ojjaara	Momelotinib Dihydrochloride	58	1,740	$1,584,109
Revlimid	Lenalidomide	60	1,504	$819,541
Vonjo	Pacritinib Citrate	39	1,170	$759,641
Empaveli	Pegcetacoplan	13	364	$522,428

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	117	$96,769	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	8	$41,528	PharmaEssentia USA Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Christopher Brent Benton, M.D.?

Tedicare shows public-source Medicare data for Christopher Brent Benton, M.D. (NPI 1255667655), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Christopher Brent Benton, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Christopher Brent Benton, M.D.?

Christopher Brent Benton, M.D. is linked to ROCKY MOUNTAIN CANCER CENTERS LLP (billing NPI 1518941186) in the available physician profile data.

Does Christopher Brent Benton, M.D. have Open Payments data?

Christopher Brent Benton, M.D. has 125 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.